Hump Day’s Stock Market Keeps It Green – $AAPL $INM $INMB $INVO $ISIG $NBSE $PLAB $TSLA Rise!

 

Happy middle of the week folks. I hope that you all had one ‘helluva’ day today. We amazingly confirmed our third consecutive positive day across board in the markets this week. Hopefully you are out spending some of that new made invested capital on a green Mercedes or whatever floats your boat. 

 

The markets indeed move forward again without the drag and/or worry from the omicron variant.Pfizer (PFE) closing at  $51.40,  -.6% did its part to make investors feel confident as it stated that their preliminary data points towards their current vaccine (3 shots worth) levels the Omicron variant and also suggested that only 2 doses protect of their good still presents catching a severe case. Belief that our politicians will successfully manage our debt ceiling also floated in the air. Three reports surfaced via the macroeconomic schedule that kept the good times rolling which included the following: the Job openings report confirmed a rise to 11.033M in October, the weekly MBA Mortgage Applications Index was confirmed to have risen by 2%, & the weekly crude oil inventories report showed a drop  by 240k barrels, while oil prices moved .7% higher to close at $72.43/bbl. The yield curve also behaved as the 2-yr yield fell 1 basis point to .68 & the 10-yr yield moved up 3 basis points to 1.51%. Basically, all or at least most points were assisting investors expectations that had been in question last week. 

 

In turn, the indices closed in the green as follows: the S&P 500 closed at 4,701.21 (+.31%), the Dow 30 closed at 35,754.75 (+.10%), & the Nasdaq closed at 15,786.99 (+.64%). Interestingly, only 8 of 11 sectors moved higher today to provide strength with the communications sector leading the with its positive .8% move. The small caps on the Russell also kept their reassurance going and closed at 2,271.71 (+.80%), while the micro caps moved up in lock step as the iShares Micro-Cap ETF (IWC) closed at $143.01, +1.27%). 

 

 

A few top performers in the large caps part of our VP Watchlist included Apple (AAPL) which closed at $175,08, +2.28% & Tesla (TSLA) closed at $1,068.96, +1.64% as Elon Musk teased the markets suggesting that more information on his Cybertruck would come to the surface soon. The Walt Disney Company (DIS) also moved up to closes at $153.34, +1.68%.

 

On the small side, Atossa Therapeutics (ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, rose to an intraday high of $2.305 prior to closing at $2.24, +4.67%. Atossa management recently held a “A Town Hall Q&A Event With Atossa Therapeutics Management Team” via Tribe Public. You can view it clicking here. Atossa also announced earlier this week that it had completed a pre-investigational new drug (PIND) meeting with the FDA to obtain input from the FDA on pre-clinical, clinical, manufacturing and regulatory matters in the U.S. for Atossa’s proprietary Z-endoxifen to treat breast cancer in the neoadjuvant (prior to surgery) setting.

 

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that management will host a virtual event entitled “B -cell Lymphoma Franchise Update” on Tuesday, December 14, 2021 at 8:00 AM ET. The event will highlight interim Phase 1 clinical data from the Company’s FT516 and FT596 programs for the treatment of relapsed / refractory B-cell lymphomas. Shares of Fate closed at $55.96, +2.51%. 

 

InMed Pharmaceuticals Inc. (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, closed at $1.60, +1.91% after hitting an intraday high of $1.63. Eric A. Adams, InMed President & CEO stated recently, “The first quarter of fiscal 2022 saw positive momentum across all of our programs. With the completion of the BayMedica Inc. (“BayMedica”) acquisition, our integrated teams are working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry. For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol® CBC (cannabichromene) and progressing our existing programs.”

 

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, recently announced two poster presentations at the 2021 British Society of Immunology Congress, which was held November 28-December 1, in Edinburgh, UK. Shares of INMB closed trading today at $12.52, +4.95%. 

 

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo culture system (IVC), INVOcell®, announced last week that the Company has received approval by Medical Devices Control Division for FDA Thailand to import and commercialize INVOcell in Thailand. In April 2021, INVO Bioscience entered an exclusive distribution agreement with IVF Envimed Company Ltd. to distribute the INVOcell system within Thailand. Established in 1993, IVF Envimed Company Ltd. has established a wide network of clinics and hospitals across Thailand primarily focused on fertility solutions. IVF Envimed is a member of the ‘Thai Society of Reproductive Medicine’ which organizes congresses and educational programs where IVF Envimed participates. Shares of INVO closed at the high of the day at $3.25., +1.56%. Recently, Steve Shum CEO of INVO stated, “We continue to execute against our core mission of improving access to advanced fertility services for the many patients around the world through the use of the INVOcell solution. During the quarter, we achieved a significant milestone with the opening of our very first INVO Center, based in Birmingham, where we have commenced initial cycles. Further, we opened clinics in Atlanta, Georgia and Monterrey, Mexico to expand the INVO Center business model and we are working to open the San Francisco Bay Area clinic as soon as possible. We completed the acquisition of a Canadian-based entity that will be used to distribute the INVOcell in Canada and to develop INVO Centers in the region. With our INVO Center strategy now successfully underway, we are optimistic on the prospects for further expansion using this unique and innovative model. As part of a detailed review, we have initially identified more than 20 cities here in the U.S. that we believe have excellent characteristics in terms of demographics and level of current fertility care that would be ideal locations for an INVO Center. As an important development to our ability to expand the INVO Center model, we will regain full U.S. commercialization rights to INVOcell® from Ferring in early 2022, which removes certain limitations we had on expanding this business model in the U.S. Further, it allows us to resume direct sales to IVF clinics in our home territory and further expand our channel development plan. With our strong team of leaders highly experienced in commercializing advanced reproductive technologies, we are optimistic about our prospects as we pursue our multi-channel market expansion strategy. In addition to the opening of our INVO Center in Monterrey, Mexico, we continue to advance our international commercialization plans. Clinical validation of INVOcell® continues to grow with four poster abstracts presented at ASRM this year. We are excited about the recent developments to advance commercialization of the INVOcell® solution. We look forward to leveraging the recent success of our INVO Centers, particularly in the U.S. With a great team, board of directors, and key advisors in place, we believe we have laid a strong foundation to achieve our goal of democratizing advanced fertility treatment with the INVOCell® solution, which should lead to strong revenue growth going forward.”

 

Shares of NeuBase Therapeutics (NASDAQ: NBSE) a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, closed higher again today at $3.16, +5.33%. 

 

FURTHER AFIELD

Ford’s (F, $19.81) CEO Jim Farley reportedly confirmed with CNBC today that it is is scrambling to meet the increasing interest in its soon-to-launch electric F-150 Lightning suggesting that their production captivity was sitting at approx. 50%. Ford also  has almost 200k. in retail reservations for its e-truck that is supposed to on showroom floors by the middle or next year. 

Shares of Insignia Systems, Inc. (NASDAQ: ISIG) powered up +84% to close at $19.11 again today as a ‘short squeeze’ seems to have been the culprit.  On December 6, Innsignia announced the commencement of a formal process to explore strategic options to maximize shareholder value. Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, in-licensing, or other strategic transaction. There can be no assurance that this process will result in any transaction. Insignia has not set a timetable for the completion of this review process and does not intend to comment further unless or until the Board of Directors has approved a definitive course of action or it is determined that other disclosure is appropriate. Chardan has been engaged to act as Insignia Systems’ strategic financial advisor to assist the Company in this review process.

Photronics, Inc. (NASDAQ:PLAB), a worldwide leader in photomask technologies and solutions, today reported financial results for its full year and fourth quarter fiscal 2021 ended October 31, 2021. Peter Kirlin, chief executive officer stated, “Photronics achieved a fourth consecutive year of record revenue, as demand for our design-driven products accelerated and we fully ramped new flat panel display capacity. We made strategic investments in 2021 that have positioned us to achieve organic growth as market trends such as the increase in demand from Asia foundries and the adoption of advanced display technologies in mobile applications have driven the market higher.” Shares of PLAB closed at $17.91, +25.95%. 

IronNet, Inc. (NYSE: IRNT), an innovative leader transforming cybersecurity through Collective Defense, will announce its third quarter fiscal 2022 financial results will be released Wednesday, December 15, 2021, after market close. Following the press release, IronNet management will host a conference call and webcast at 5 p.m. ET. Shares of IRNT closed at $8.05. 

TOMORROW

The macroeconomic schedule will deliver the weekly Initial and Continuing Claims report and the Wholesale Inventories report for October.